Gilead Sciences, Inc. $GILD Shares Sold by QRG Capital Management Inc.

QRG Capital Management Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 24.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 227,252 shares of the biopharmaceutical company’s stock after selling 72,335 shares during the period. QRG Capital Management Inc.’s holdings in Gilead Sciences were worth $25,225,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. GoalVest Advisory LLC boosted its position in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new position in Gilead Sciences during the third quarter worth about $26,000. Harbor Asset Planning Inc. purchased a new stake in shares of Gilead Sciences in the second quarter valued at about $27,000. Putney Financial Group LLC grew its position in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute purchased a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $30,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Citigroup increased their target price on Gilead Sciences from $135.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Mizuho increased their price objective on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 3rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a report on Friday, October 31st. Finally, Argus raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $133.16.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director owned 8,920 shares in the company, valued at $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $124.83, for a total transaction of $1,248,300.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at $70,740,911.34. This trade represents a 1.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 136,757 shares of company stock valued at $16,951,612 over the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $124.91 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences, Inc. has a 1-year low of $91.68 and a 1-year high of $128.70. The company has a market capitalization of $154.97 billion, a price-to-earnings ratio of 19.37, a PEG ratio of 0.64 and a beta of 0.33. The business has a 50-day moving average of $123.36 and a 200-day moving average of $118.02.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s payout ratio is 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.